Materias dentro de su búsqueda.
Mostrando 2,141 - 2,160 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.35s Limitar resultados
  1. 2141
    “…Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for the selection of breast cancer patients for trastuzumab therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
  2. 2142
    “…The aim of this study was to evaluate whether the HER2 expression in breast cancer is retained in metastases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
  3. 2143
    por Jacot, W, Pujol, J-L, Boher, J-M, Lamy, P-J
    Publicado 2004
    “…It was not possible to discriminate between lung cancer and benign lung disease owing to the lack of sensitivity–specificity relationship of HER-2 and EGFR ECD levels. Neither HER-2 nor EGFR ECD specific levels were associated with a particular prognosis of NSCLC patients receiving conventional therapy.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
  4. 2144
    “…Human epidermal growth factor receptor (HER)2 over-expression is associated with a shortened disease-free interval and poor survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
  5. 2145
    “…BACKGROUND: In Her2-positive advanced breast cancer, the upfront use of trastuzumab is well established. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
  6. 2146
    “…And only those cases with Her-2 status of IHC 3+ or FISH positive should be treated with Herceptin.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
  7. 2147
    “…Several attempts have been made using the extracellular domain of Her2/neu (ECD/Her2) as a prophylactic vaccine in mice with no success in tumor prevention. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity
  8. 2148
    “…Therefore, NIH3T3 fibroblasts, conditionally expressing the human epidermal growth factor receptor 2 (HER2/neu), were implanted into the dorsal skin of nude mice, and tumor growth in treated animals was compared to control mice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model
  9. 2149
    “…Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody directed against an extracellular region of the HER2 protein. We hypothesized that a single adeno-associated virus mediated genetic delivery of an anti-HER2 antibody should be effective in mediating long term production of anti-HER2 and in suppressing the growth of human tumors in a xenograft model in nude mice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Persistent Expression of Biologically Active Anti-HER2 Antibody by AAVrh.10-mediated Gene Transfer
  10. 2150
    “…Dobson L, Conway C, Hanley A, Johnson A, Costello S, O’Grady A, Connolly Y, Magee H, O’Shea D, Jeffers M & Kay E (2010) Histopathology57, 27–38 Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation AIMS: Accurate determination of HER-2 status is critical to identify patients for whom trastuzumab treatment will be of benefit. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation
  11. 2151
    “…INTRODUCTION: HER2 gene amplification and protein overexpression (HER2+) define a clinically challenging subgroup of breast cancer with variable prognosis and response to therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
  12. 2152
    por Vogel, Ulrich F
    Publicado 2010
    “…The routinely assigned low rate of 9% of HER2-overexpressed breast carcinomas alarmed one of our gynecologists who requested to confirm our HER2 test results. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
  13. 2153
    “…In this study, through modular design, we generated a recombinant fusion protein designated as Her-nuclear localization sequence (Her-NLS), where heregulin-α (Her), a targeting moiety, was cloned in frame with cationic NLS peptide to obtain a cell-specific targeting biomolecule for nucleic acid delivery. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein
  14. 2154
    “…CONCLUSION: These data demonstrate that EGFR and HER2 pathways are suitable therapeutic targets for BTCs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
  15. 2155
    “…We show that plant-made trastuzumab (PMT) bound to the Her2/neu oncoprotein of SK-BR-3 cells and efficiently inhibited SK-BR-3 cell proliferation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
  16. 2156
    “…In addition, markers for glial precursors and mature glial cells were down-regulated in Her8a morphants, suggesting Her8a is required for gliogenesis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Zebrafish Her8a Is Activated by Su(H)-Dependent Notch Signaling and Is Essential for the Inhibition of Neurogenesis
  17. 2157
    por Wang, Shizhen Emily
    Publicado 2011
    “…Accumulating evidence indicates a functional crosstalk between the HER2 (ErbB2) tyrosine kinase and the TGF-β signaling mediated by its serine/threonine kinase receptors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy
  18. 2158
    “…As malignancy further progressed, we identified a subset of cells harbouring HER2 amplification. Our results recognize YB-1 as a cancer susceptibility gene with the capacity to prime cells for tumourigenesis.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction, and HER2 amplification
  19. 2159
    “…The relationships between Her2 and Her3 protein expression and clinicopathological parameters/survival of HNSCC patients were analyzed with immunohistochemistry. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma
  20. 2160
    “…We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling
Herramientas de búsqueda: RSS